Evidence map›Paper›PMID 36066597›Full record

ReviewIntensive care medicine2022

Delivering optimal renal replacement therapy to critically ill patients with acute kidney injury.

Ron Wald, William Beaubien-Souligny, Rahul Chanchlani, Edward G Clark, Javier A Neyra, Marlies Ostermann, Samuel A Silver, Suvi Vaara, Alexander Zarbock, Sean M Bagshaw

Abstract readReview
PubMed Publisher
In one paragraph

Review in Intensive care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Regional Citrate Anticoagulation or Heparin Anticoagulation for Renal Replacement Therapy in Patients With Liver Failure: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Review
  11. Therapeutic Effects ofPediatric discovery · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. "High blood flow" versus "low blood flow" ECCOCritical care (London, England) · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 5 countries.

Ron WaldDivision of Nephrology, St. Michael's Hospital and the University of Toronto, 61 Queen Street East, 9-140, Toronto, ON, M5C 2T2, Canada. Ron.wald@unityhealth.to.ORCID http://orcid.org/0000-0003-4411-8169
William Beaubien-SoulignyDivision of Nephrology, Centre Hospitalier de L'Université de Montréal, Montréal, QC, Canada.
Rahul ChanchlaniDivision of Pediatric Nephrology, Department of Pediatrics, McMaster University, Hamilton, ON, Canada.
Edward G ClarkDivision of Nephrology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Javier A NeyraDivision of Nephrology, University of Alabama at Birmingham, Birmingham, AL, USA.
Marlies OstermannDepartment of Critical Care Medicine, Guys and St. Thomas Hospital, London, UK.
Samuel A SilverDivision of Nephrology, Kingston Health Sciences Center, Queen's University, Kingston, ON, Canada.
Suvi VaaraDivision of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Alexander ZarbockDepartment of Anesthesiology, Intensive Care and Pain Medicine, Muenster, Germany.
Sean M BagshawDepartment of Critical Care Medicine, University of Alberta and Alberta Health Services, Edmonton, AB, Canada.
Alberta Health Services · CAAugenstern · DECentre Hospitalier de l’Université de Montréal · CAMcMaster University · CAQueen's University · CASt. Michael's Hospital · CASt Thomas' Hospital · GBUniversity of Alabama at Birmingham · USUniversity of Helsinki · FIUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Critical illness is often complicated by acute kidney injury (AKI). In patients with severe AKI, renal replacement therapy (RRT) is deployed to address metabolic dysfunction and volume excess until kidney function recovers. This review is intended to provide a comprehensive update on key aspects of RRT prescription and delivery to critically ill patients. Recently completed trials have enhanced the evidence base regarding several RRT practices, most notably the timing of RRT initiation and anticoagulation for continuous therapies. Better evidence is still needed to clarify several aspects of care including optimal targets for ultrafiltration and effective strategies for RRT weaning and discontinuation.

Indexed as

Acute Kidney InjuryCritical IllnessHumansIntensive Care UnitsRenal Replacement TherapyAcute kidney injuryClinical trialsIntensive care unitRenal replacement therapy

Identifiers

PMID36066597
OpenAlexW4294794370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.